Centogene N.V.'s latest marketcap:
As of 08/05/2025, Centogene N.V.'s market capitalization has reached $1.79 M. According to our data, Centogene N.V. is the 47098th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.79 M |
| Revenue (ttm) | 53.65 M |
| Net Income (ttm) | -39,274,898 |
| Shares Out | 29.82 M |
| EPS (ttm) | -1.4 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/05/2025 |
Centogene N.V.'s yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 08/05/2025 | $1.79 M | -52% | 47098 |
| 12/31/2024 | $3.93 M | -88.24% | 47119 |
| 12/29/2023 | $33.44 M | 32.77% | 45454 |
| 12/30/2022 | $25.19 M | -78.6% | 43740 |
| 12/31/2021 | $117.7 M | -50.06% | 41759 |
| 12/31/2020 | $235.67 M | 17.83% | 38608 |
| 12/31/2019 | $200 M | 35985 |
Company Profile
About Centogene N.V.
Centogene N.V., along with its subsidiaries, delivers pharmaceutical solutions and diagnostic tests across Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company specializes in providing data-driven insights for rare and neurodegenerative diseases, serving patients, physicians, and pharmaceutical companies.
Key Offerings
- CENTOGENE MOx 2.0: A multiomic solution integrating DNA sequencing, biochemical testing, and RNA sequencing.
- CentoCloud: A cloud-based SaaS platform for genomic variant analysis, interpretation, and reporting in rare disease diagnostics.
- FilterTool: A web-based application designed for genetic data interpretation.
- NEW CentoGenome: A Next Generation Sequencing (NGS)-based assay that accelerates access to potential treatments.
Additional Services
- Target and drug screening, clinical development, and market expansion support.
- Licenses for CENTOGENE Biodatabank and insight reports.
- Early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring.
- Genetic sequencing and diagnostics, including whole exome sequencing, whole genome sequencing, and multiomic testing solutions.
Founded in 2006, Centogene N.V. is headquartered in Rostock, Germany.
Frequently Asked Questions
-
What is Centogene N.V.'s (OTC-CNTGF) current market cap?As of 08/05/2025, Centogene N.V. (including the parent company, if applicable) has an estimated market capitalization of $1.79 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Centogene N.V. (OTC-CNTGF) rank globally by market cap?Centogene N.V. global market capitalization ranking is approximately 47098 as of 08/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.